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OBJECTIVEdTo test whether inhibiting inflammation with salsalate improves endothelial
function in patients with type 2 diabetes (T2D).
RESEARCH DESIGN AND METHODSdWe conducted an ancillary study to the
National Institutes of Health–sponsored, multicenter, randomized, double-masked, placebo-
controlled trial evaluating the safety and efficacy of salsalate in targeting inflammation to improve
glycemia in patients with T2D. Flow-mediated, endothelium-dependent dilation (FMD) and
endothelium-independent, nitroglycerin-mediated dilation (NMD) of the brachial artery were
assessed at baseline and 3 and 6 months following randomization to either salsalate 3.5 g/day or
placebo. The primary end point was change in FMD at 6 months.
RESULTSdA total of 88 participants were enrolled in the study, and data after randomi-
zation were available for 75. Patients in the treatment and control groups had similar ages (56
years), BMI (33 kg/m2), sex (64% male), ethnicity, current treatment, and baseline HbA1c
(7.7% [61 mmol/mol]). In patients treated with salsalate versus placebo, HbA1c was reduced
by 0.46% (5.0 mmol/mol; P, 0.001), fasting glucose by 16.1 mg/dL (P, 0.001), and white
blood cell count by 430 cells/mL (P , 0.02). There was no difference in the mean change in
either FMD (0.70% [95% CI20.86 to 2.25%]; P = 0.38) or NMD (20.59% [95% CI22.70 to
1.51%]; P = 0.57) between the groups treated with salsalate and placebo at 6 months. Total
and LDL cholesterol were 11 and 16 mg/dL higher, respectively, and urinary albumin was
2.0 mg/mg creatinine higher in the patients treated with salsalate compared with those treated
with placebo (all P , 0.009).
CONCLUSIONSdSalsalate does not change FMD in peripheral conduit arteries in patients
with T2D despite lowering HbA1c. This finding suggests that salsalate does not have an effect on
vascular inflammation, inflammation does not cause endothelial dysfunction in T2D, or con-
founding effects of salsalate mitigate favorable effects on endothelial function.
Diabetes Care 36:4132–4139, 2013
A therosclerosis is the principal causeof death and disability among pa-tients with type 2 diabetes (T2D), in
whom it typically occurs earlier, with greater
severity, and with more diffuse distribution
(1). Chronic subacute inflammation is asso-
ciated with obesity, insulin resistance and
T2D, and atherosclerosis (reviewed by
Shoelson et al. [2] and Libby [3]). Anti-
inflammatory salicylates, which inhibit
the nuclear factor (NF)-kB signaling path-
way, are being studied as a potential new
class of drugs for the treatment of these
disorders, and recent studies have shown
that targeting inflammation with salsalate
can improve glycemia in patients with
obesity and T2D (4–7).
Diabetes exerts its proatherogenic
actions in part by disturbing endothelial
homeostasis. Endothelium-dependent
vasodilation, a marker of atherosclerosis,
is impaired in patients with atheroscle-
rotic risk factors, including diabetes (8–
11). Endothelial function in peripheral
conduit arteries reflects function in the
human coronary circulation (12), and im-
paired endothelium-dependent vasodila-
tion predicts cardiovascular events
(13,14). Flow-mediated, endothelium-
dependent dilation (FMD) can be quanti-
tated as an index of vasomotor function,
and the noninvasive nature of the tech-
nique permits repeated measurements
over time to evaluate the effectiveness of
interventions that may affect vascular
health. Thus, we sought to test the
hypothesis that targeting inflamma-
tion will improve endothelial function.
We evaluated FMD as an informative
surrogate marker of cardiovascular
health following a therapeutic trial of
salsalate, a novel agent being evaluated
to treat T2D.
RESEARCH DESIGN AND
METHODS
Trial design
The Targeting Inflammation Using Salsa-
late in Type 2 Diabetes (TINSAL-T2D)
stage 2 trial was conducted as a single-
mask lead-in, randomized, double-
masked, placebo-controlled, multicenter
clinical trial. In brief, the protocol, ap-
proved by human subject institutional
review boards at each institution, in-
cluded 1 week of screening; a 4-week,
single-masked placebo run-in; a base-
line evaluation before treatment; and a
48-week treatment period, with computer-
generated (1:1) randomized allocation to
salsalate (3.5 g/day divided) or a placebo
that appeared identical, as described in
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detail (15). Inclusion criteria included
T2D, age 18 to 75 years, and HbA1c levels
of 7–9.5% (53–80 mmol/mol) at screen-
ing. Concomitant oral diabetes medica-
tion had to be at stable dosages for at
least the previous 8 weeks. Patients who
received low-dose aspirin (81–325 mg/
day) also were eligible for the trial. Key
exclusion criteria included use of thiazo-
lidinediones, insulin, or glucagon-like
peptide-1 receptor agonists; chronic use
of nonsteroidal anti-inflammatory drugs,
anticoagulants, or uricosuric agents; and
impaired renal function with an estimated
glomerular filtration rate ,60 mL/min
and/or urinary albumin.300 mg/mg cre-
atinine. The Effect of Targeting Inflamma-
tion Using Salsalate on Flow-Mediated
Dilation (TINSAL-FMD) was conducted
as an ancillary study to the parent trial.
Seven academic sites within the United
States participated in the ancillary study.
The protocol was approved by the human
subject institutional review boards at each
institution.
Vascular function studies were per-
formed at baseline (visit 3, week 0) before
randomization; at 3 months (visit 7, week
12); and at 6 months (visit 9, week 24).
All nitric oxide potentiating drugs (e.g.,
phosphodiesterase type 5 inhibitors)
were suspended for 1 week, and all
antihypertensive and vasoactive drugs,
alcohol, and caffeine were held for at
least 12 h before vascular function
measurements.
Central training and FMD methods
Endothelial function was determined in
accordance with published guidelines
(16). All sites received central training
and underwent certification procedures
to establish a uniform methodology.
Each of the sites submitted to the core
imaging laboratory sample images ac-
quired from at least three volunteers for
review to demonstrate the site’s ability to
acquire technically adequate images for
interpretation before any research subject
was enrolled at the site. All sites had ul-
trasound equipment capable of simulta-
neous B-mode and electrocardiographic
monitoring, with an electrocardiographic
trigger, DICOM file storage capacity, a
Hokanson SC5 (or equivalent 6- 3 83-cm)
blood pressure cuff with a manual cuff
inflator, and an automatic blood pres-
sure monitor. Subjects were studied in a
quiet, temperature-controlled, dimly lit
room after resting supine for a minimum
of 5 min. High-resolution B-mode ultra-
sonography of the brachial artery was
performed using a 7.5-MHz linear array
probe. The brachial artery was imaged
longitudinally just proximal to the ante-
cubital fossa with the transducer position
adjusted to obtain optimal images of the
near and far wall of the intima. The R wave
on the electrocardiogram served as a trig-
ger to acquire digitized image frames at
end diastole. After acquiring a baseline
image, a sphygmomanometric cuff placed
on the upper portion of the arm was in-
flated to suprasystolic pressure (200
mmHg) for 5 min. When the cuff is re-
leased, reactive hyperemia causes flow to
increase through the brachial artery sub-
serving the forearm. The velocity time in-
tegral was assessed by pulse Doppler
within 15 s of cuff release to assess the
peak velocity of hyperemic blood flow.
FMD of the brachial artery was deter-
mined with images acquired 1 min after
cuff deflation. FMD at this time point is
largely endothelium-dependent and me-
diated by nitric oxide, and it can be in-
hibited by administration of the nitric
oxide synthase antagonist NG-monomethyl-L-
arginine (17). Ten minutes after release of
the cuff, the brachial artery was re-imaged
to ensure a return to basal conditions.
Then, to determine nitroglycerin-mediated
endothelium-independent vasodilation
(NMD), subjects received sublingually
0.4 mg of nitroglycerin. The brachial ar-
tery was imaged 3 min later. Nitroglyc-
erin was not administered if the systolic
blood pressure was,100 mmHg. All im-
ages were analyzed at a central core lab-
oratory by a single reader masked to
treatment assignment. In the core labora-
tory, the intraobserver (operator) vari-
ability is 0 6 0.15%. Arterial diameter
during each experimental condition was
measured using edge detection software
(Brachial Analyzer for Research, version
5.8.9 SP-2; Medical Imaging Applications
LLC, Coralville, IA).
Primary and secondary outcomes
The primary outcome of this study was
the change in FMD from baseline to
6-month follow-up in the group treated
with salsalate compared with the group
treated with placebo. Change in NMD
was an important secondary outcome.
Laboratory measures
Unless otherwise noted, laboratory mea-
surements were performed at Quest Di-
agnostics (Chantilly, VA). Commercial
immunoassays were used according to
instructions for insulin and C-peptide
(Mercodia, Upsala, Sweden), adiponectin,
cystatin C, high-sensitivity C-reactive pro-
tein (CRP), tumor necrosis factor (TNF)
and TNF receptors (ELISA kits from R &
D Systems, Minneapolis, MN), and free
fatty acids (reagents from VWR Interna-
tional, Radnor, PA).
Statistical analyses
Weanalyzed thedata following the intention-
to-treat principle. All patients with data at
the baseline FMD measurement and up
to the point of dropout (if dropout oc-
curred) were included in the analyses.
Differences in baseline characteristics
were compared between treatment
groups using Student t test for normally
distributed continuous traits and x2 or
Fisher exact test for categorical traits.
For normally distributed continuous out-
comes we estimated mean differences be-
tween treatment groups using linear
regression mixed models, including
FMD measurements adjusted for base-
line levels over the 26-week study
period. We assumed an autoregressive
moving average covariance structure.
For continuous outcomes with non-
parametric distributions we used the
Wilcoxon test to compare change from
baseline between the placebo and salsalate
groups at week 24. All statistical tests
report two-sided P values; P , 0.05
was considered significant. TheHolm pro-
cedure was used to correct for multiple
comparisons (18).
We calculated the sample size based
on mean and standard deviations of
change in flow-mediated vasodilation for
patients with diabetes following placebo
(10). Because vascular measurements
would be made at several centers we an-
ticipated that the variation in measure-
ments of the mean change from baseline
would be 2.5-fold higher than the reported
variation of 1.2%. Accordingly, based on
an anticipated improvement of 25% in
flow-mediated endothelium-dependent
vasodilation in the group treated with sal-
salate compared with the group treated
with placebo at 6 months and an estimated
standard deviation of the mean change
from baseline of 3.0%, we estimated
that a total of 72 completed participants
would be necessary for this study.
RESULTS
Baseline characteristics
Baseline characteristics of TINSAL-T2D
subjects participating in the TINSAL-
FMD ancillary study were balanced be-
tween the salsalate and placebo groups
care.diabetesjournals.org DIABETES CARE, VOLUME 36, DECEMBER 2013 4133
Goldfine and Associates
(Table 1). We enrolled 91 participants in
the ancillary study. Of these, 88 partici-
pants completed the baseline assessment
and 3 were unable to schedule baseline
evaluations; 68 participants had visits at
baseline, 3 months, and 6 months, 7 had
visits at only baseline and 3 months, and
13 had only a baseline visit (Fig. 1). We
excluded patients with only a baseline
visit, leaving 75 patients for whom data
after randomization were available for
analysis. There was no statistical differ-
ence in the sex of the participants between
the treatment groups.
Participants in the TINSAL-FMD an-
cillary study had lower systolic blood
pressure and total cholesterol and were
more likely to be treated with an insulin
secretagogue, antihypertensive medica-
tion (especially an angiotensin-converting
enzyme inhibitor or angiotensin receptor
Table 1dBaseline characteristics of participants in the parent TINSAL-T2D study compared with the TINSAL-FMD ancillary study and
characteristics by treatment group
Characteristics
TINSAL-T2D study
(n = 286)
TINSAL-FMD study
(n = 75) Placebo (n = 38)
Salsalate
(n = 37)
Age (years) 55.8 6 9.6 56.4 6 10.1 57.1 6 11.8 55.6 6 7.9
Male sex 156 (54.6) 48 (64.0) 23 (60.5) 25 (67.6)
Race/ethnicity
White 151 (52.8) 46 (61.3) 23 (60.5) 23 (62.2)
Black 95 (33.2) 25 (33.3) 13 (34.2) 12 (32.4)
Other 40 (14.0) 4 (5.3)* 2 (5.3) 2 (5.4)
Weight (kg) 96.2 6 22.5 97.9 6 23.0 94.2 6 21.7 101.7 6 23.9
BMI (kg/m2) 33.3 6 6.7 33.1 6 6.7 32.2 6 7.5 33.9 6 5.9
Time since diabetes diagnosed (years)a 4.9 (0.1, 38.3) 4.1 (0.2, 35.0) 3.6 (0.2, 35.0) 4.4 (0.6, 23.8)
Medical history
CADb 32 (11.2) 10 (13.3) 5 (13.2) 5 (13.5)
Hypertensionc 208 (72.7) 59 (78.7) 30 (79.0) 29 (78.4)
Dyslipidemiad 199 (69.6) 60 (80.0)* 30 (79.0) 30 (81.1)
Blood pressure (mmHg)
Systolic 126.1 6 13.4 121.9 6 13.9* 120.1 6 15.3 123.9 6 12.2
Diastolic 76.5 6 8.5 74.8 6 8.5 74.5 6 8.1 75.2 6 9.0
Heart rate (bpm) 72.9 6 10.2 72.3 6 11.9 70.4 6 12.6 74.1 6 10.9
Laboratory values
HbA1c (%)
e 7.7 6 0.7 7.7 6 0.8 7.6 6 0.8 7.8 6 0.7
Fasting glucose (mg/dL) 151 6 38 146 6 35 143.7 6 34.4 148.5 6 26.7
Cholesterol (mg/dL) 165 6 41 155 6 42 155.2 6 47.7 155.2 6 36.8
Triglycerides (mg/dL)a 137 (45, 605) 151 (45, 531) 132 (45, 334) 163 (63, 531)
LDL (mg/dL) 102.0 6 33.2 96.0 6 33.6 94.8 6 37.8 97.2 6 29.2
Urinary albumin (mg/mg creatinine)a 8 (1, 350) 7 (1, 310) 7 (1, 310) 7 (2, 100)
Medications
Metformin 252 (88.1) 68 (90.7) 34 (89.5) 34 (91.9)
Insulin secretagogue 149 (52.1) 49 (65.3)* 22 (57.9) 27 (73.0)
DPP-4 inhibitor 43 (15.0) 7 (9.3) 3 (7.9) 4 (10.8)
Lifestyle only 13 (4.6) 3 (4.0) 1 (2.6) 2 (5.4)
Monotherapy 117 (40.9) 24 (32.0) 16 (42.1) 8 (21.6)
Dual therapy 140 (49.0) 44 (58.7) 20 (52.6) 24 (64.9)
Lipid medications
Lipid medicationf 180 (62.9) 55 (73.3)* 26 (68.4) 29 (78.4)
Statin 171 (59.8) 52 (69.3)* 25 (65.8) 27 (73.0)
Other 28 (9.8) 9 (12.0) 3 (7.9) 6 (16.2)
Blood pressure medications
Antihypertensive medicationg 185 (64.7) 56 (74.7) 28 (73.7) 28 (75.7)
ACEI/ARB 159 (55.6) 49 (65.3)* 24 (63.2) 25 (67.6)
Other antihypertensive 111 (38.8) 34 (45.3) 20 (52.6) 14 (37.8)
Low-dose aspirinh 116 (40.6) 32 (42.7) 15 (39.5) 17 (46.0)
Data are n (%) ormean6 SD unless otherwise indicated. *P, 0.05 for the comparison between participants in the parent TINSAL-T2D trial with those in the TINSAL-
FMD ancillary study. aMedian (minimum, maximum) values are reported, and the statistical difference was tested on logarithmic transformed variables. bCAD
(coronary artery disease) is defined as history of stroke, myocardial infarction, angina, or revascularization coronary artery bypass graft/percutaneous transluminal
coronary angioplasty. cHypertension is defined as systolic blood pressure .140 mmHg or diastolic blood pressure .90 mmHg or taking antihypertensive medi-
cation. dDyslipidemia is defined as LDL .150 mg/dL or taking lipid-lowering medication. eTo convert %HbA1c = [0.09148 3 IFCC (mmol/mol)] + 2.152.
fA participant can be taking both a statin and an “other” lipid medication but is counted as being on lipid medication only once. gA participant can be taking both an
angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and an “other” antihypertensive agent but is counted as being on antihy-
pertensive medication only once. hLow-dose aspirin is 80–325 mg/day.
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Salsalate’s effects on flow-mediated dilation
blocker), and lipid-lowering therapy
(especially hydroxymethylglutaryl-
CoA reductase inhibitors [statins])
compared with the parent trial popula-
tion (Table 1).
Effect of salsalate on endothelial
function
The baseline brachial artery diameter was
3.91 6 0.62 mm in the group treated
with salsalate versus 4.11 6 0.66 mm in
the group treated with placebo (P = 0.19).
The baseline peak hyperemic blood flow,
reported as the maximal hyperemic veloc-
ity time integral (the ratio of time aver-
aged systolic velocity [centimeters/
second] divided by the time of the cardiac
cycle [seconds]), measured after cuff de-
flation, was 62.8 cm (interquartile range
42.0) in the group treated with salsalate
and 69.6 cm (interquartile range 54.0) in
the group treated with placebo (P = 0.37
between groups). There was no signifi-
cant change after treatment in either bra-
chial artery diameter or peak hyperemic
velocity integral in either the salsalate or
placebo treatment groups. Baseline FMD
was 6.43 6 4.55% in the salsalate group
and 5.92 6 4.02% in the placebo group.
Baseline NMD was 13.146 6.09% in the
salsalate group and 11.786 6.57% in the
placebo group. Compared with placebo,
salsalate had no effect on the change in
FMD at either 12 or 24 weeks of treatment
(P = 0.38) (Fig. 2A). Likewise, salsalate
had no effect on change in NMD (P =
0.57) (Fig. 2B).
Effect of salsalate on metabolic and
cardiorenal risk factors
The effects of salsalate on metabolic
and cardiorenal outcomes for the entire
TINSAL-T2D cohort are reported by
Goldfine et al. (15). The effects were sim-
ilar in magnitude for glycemic, blood
pressure, lipid, and inflammatory param-
eters in the TINSAL-FMD cohorts. Both
HbA1c and fasting glucose were lowered in
the group treated with salsalate compared
with placebo (Table 2). There was no differ-
ence between treatment groups for systolic
and diastolic blood pressures. LDL and uri-
nary albumin, however, increased in the
group treated with salsalate compared
with placebo. The anti-inflammatory
properties of salsalate were evident by re-
ductions in circulating total white blood
cell (WBC) and lymphocyte counts and
an increase in adiponectin. There was no
difference between treatment groups in
the change in high-sensitivity CRP, TNF-a,
or the TNF receptors 1 or 2.
CONCLUSIONSdThe primary find-
ing of this study is that salsalate had no
effect on FMD of the brachial artery in
patients with T2D. In this study we
evaluated salsalate administered over
6 months at a dose that is tolerated by
the majority of patients and is under
evaluation for therapeutic use in the treat-
ment of T2D. Both HbA1c and fasting glu-
cosewere lowered in the group treatedwith
salsalate compared with the group treated
with placebo, demonstrating the positive
Figure 1dTINSAL-FMD study enrollment, randomization, and retention of the study
participants.
Figure 2dFMD (A) and nitroglycerin (NTG)-mediated dilation (B) are shown for participants
treated with placebo and salsalate. There was no difference in the change in FMD (the primary
outcome of this study) or NTG-mediated vasodilation from baseline to the 6-month follow-up
in the group treated with salsalate compared with the group treated with placebo. w12, week 12;
w24, week 24.
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effects of salsalate on glycemia. The anti-
inflammatory effects of salsalate also were
evident in the lower circulating total WBC
and lymphocyte counts in the group treated
with salsalate, even though there was no
difference in the change in CRP between
groups. Potentially adverse effects on
lipids and renal function were seen.
Salsalate treatment increased total and
LDL cholesterol but did not affect HDL;
it also increased urinary albumin, albeit
without changing estimates of the glo-
merular filtration rate.
There are several potential explana-
tions for our findings that neither support
nor refute the findings that NF-kB expres-
sion and/or activity are increased in the
endothelium of people who are resistant
to insulin, with differential effects in pa-
tients with and without diabetes (19,20).
First, salicylate levels achieved at the tol-
erable doses of salsalate used in this study
may have minimal or no effect on endo-
thelial function in people with established
T2D. In a report by Pierce and colleagues
(21), salsalate administered to overweight
patients at higher doses (4.5 g/day) over
4 days increased the inhibition of NF-kB
expression, reduced nuclear expression of
NF-kB in endothelial cells, and improved
Table 2dEffect of salsalate on selected clinical and laboratory values
Outcome measure
Treatment
group Mean change (95% CI) P value
Mean difference between
treatment groups* (95% CI) P value
Systolic blood pressure (mmHg) Placebo 4.8 (2.6–7.1) ,0.001
Salsalate 4.4 (2.0–6.7) ,0.001 20.5 (23.7 to 2.7) 0.763
Diastolic blood pressure (mmHg) Placebo 1.9 (0.3–3.4) 0.020
Salsalate 2.1 (0.5–3.7) 0.011 0.22 (22.0 to 2.4) 0.845
HbA1c (%)* Placebo 20.06 (20.23 to 0.10) 0.445
Salsalate 20.52 (20.69 to 20.35) ,0.001 20.46 (20.69 to 20.22) ,0.001
Glucose (mg/dL) Placebo 1.7 (23.7 to 7.2) 0.530
Salsalate 214.3 (220.0 to 28.7) ,0.001 216.1 (223.9 to 28.2) ,0.001
Cholesterol (mg/dL) Placebo 2.0 (23.7 to 7.6) 0.495
Salsalate 12.8 (7.0–18.7) ,0.001 10.9 (2.8–18.9) 0.009
HDL (mg/dL) Placebo 0.9 (20.3 to 2.0) 0.144
Salsalate 1.8 (0.6–3.0) 0.004 0.9 (20.8 to 2.6) 0.282
LDL (mg/dL) Placebo 21.1 (26.2 to 4.1) 0.687
Salsalate 14.6 (9.2–19.9) ,0.001 15.6 (8.2–23.0) ,0.001
Triglyceride (mg/dL)† Placebo 3.0 (26.8 to 13.6) 0.538
Salsalate 215.0 (225.2 to 23.2) 0.014 215.0 (226.9 to 21.7) 0.027
Albumin-to-creatinine ratio
(mg protein/mg creatinine)† Placebo 3.4 (0.81–6.4) 0.007
Salsalate 25.3 (18.2–33.8) ,0.001 11.7 (6.3–4.6) ,0.001
WBC (mcL) Placebo 20 (222 to 26) 0.862
Salsalate 241 (267 to 216) 0.002 243 (279 to 28) 0.016
Lymphocytes (mcL) Placebo 23 (290 to 137) 0.684
Salsalate 2340 (2458 to 2222) ,0.001 2363 (2527 to 2200) ,0.001
Monocytes (mcL) Placebo 37 (8–66) 0.013
Salsalate 33 (3–64) 0.033 24 (246 to 38) 0.858
Neutrophils (mcL) Placebo 266 (2289 to 157) 0.557
Salsalate 2113 (2348 to 121) 0.338 247 (2372 to 277) 0.772
Free fatty acids (mmol/L) Placebo 15.9 (236.8 to 68.5) 0.548
Salsalate 33.8 (221.5 to 89.1) 0.226 17.9 (258.3 to 94.1) 0.640
Adiponectin (mg/mL)† Placebo 1.1 (1.8–2.0) 0.010
Salsalate 6.1 (4.5–7.7) ,0.001 3.1 (1.6–4.7) ,0.001
hs-CRP (mg/L)† Placebo 0.97 (21.38 to 3.84) 0.573
Salsalate 20.15 (23.18 to 3.59) 0.921 20.10 (23.71 to 2.64) 0.643
Insulin (mU/mL)† Placebo 20.33 (21.56 to 1.05) 0.717
Salsalate 2.06 (20.11 to 4.19) 0.053 1.78 (20.28 to 4.21) 0.100
C-peptide (ng/mL) Placebo 21.6 (24.2 to 1.0) 0.221
Salsalate 24.7 (27.3 to 22.0) 0.001 23.0 (26.8 to 0.7) 0.110
TNF-a (pg/mL)† Placebo 33.8 (29.5–38.5) ,0.001
Salsalate 51.0 (44.6–58.2) ,0.001 0.9 (20.8 to 2.8) 0.309
TNFR1 (ng/mL)† Placebo 20.3 (18.4–22.4) ,0.001
Salsalate 27.3 (24.6–30.1) ,0.001 20.2 (21.1 to 0.9) 0.742
TNFR2 (ng/mL)† Placebo 67.1 (61.2–73.4) ,0.001
Salsalate 99.1 (90.3–108.7) ,0.001 0.8 (20.5 to 2.2) 0.257
*To convert %HbA1c = [0.09148 3 IFCC (mmol/mol)] + 2.152. †Test is based on natural log transformation; results are back-transformed and the change ratio is
multiplied by the group mean. hs-CRP, high-sensitivity CRP; TNFR, TNF receptor.
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endothelial function. However, these
higher doses of salsalate are poorly toler-
ated and would not be feasible for ex-
tended administration (5,21). In
addition, the positive effect of salsalate
on endothelial function that was demon-
strated following short-term exposure
(21) may not be sustained.
Second, the participants in the TINSAL-
FMD ancillary study had a higher
disease index compared with the partici-
pants in the parent TINSAL-T2D study;
this was manifest in the greater use of dual
therapy and sulfonylureas at baseline toman-
age diabetes and statins and angiotensin-
converting enzyme inhibitors/angiotensin
receptor blockers to manage lipids and
hypertension, respectively. It is possible
that targeting inflammation with salsalate
has few additional beneficial effects on
endothelial function in advanced disease
or when added to lipid-lowering and
antihypertensive therapies (22–24). In-
deed, we recently found that salsalate
did not change endothelial function, as
assessed by peripheral arterial tonogra-
phy, in patients with prediabetes, many
of whom also were taking therapies to
lower lipids and blood pressure (25).
Third, confounding effects of salsalate
on lipids and renal function may mitigate
any improvements in endothelial func-
tion derived from salsalate such that the
net effect is neutral. The mechanisms of
increased LDL cholesterol and urinary al-
bumin remain unknown. It is interesting
that increased LDL concentrations have
been observed with several classes of
anti-inflammatory agents, including inhi-
bition of TNF-a and interleukin (IL)-6
(26,27). High circulating WBC counts
occur in patients with obesity and the
metabolic syndrome (28) and predict in-
cident T2D (29,30) and cardiovascular
disease as well as poor outcomes in the
latter (31–33), suggesting that reductions
in the WBC count may benefit individuals
with cardiometabolic risk. WBC counts
are lowered by salsalate but, interestingly,
not by statins. Salsalate lowered WBC
counts in this study, even though the
vast majority of study patients were taking
statins. In contrast, salsalate had little ef-
fect on CRP levels in either the overall
TINSAL-T2D trial or this FMD ancillary
study, although CRP is lowered by statins.
These findings are consistent with the
notion that the anti-inflammatory effects
of salsalate are independent from those
of statins. Likewise, nonsteroidal anti-
inflammatory drugs are not known to lower
WBC counts, thus further distinguishing
these anti-inflammatory drug classes and
potential mechanisms.
Diets rich in calories, animal fats, and
sugars have been shown to induce a state
of chronic subacute inflammation and
promote dyslipidemia, fatty liver, insulin
resistance, T2D, and cardiovascular dis-
ease. At the molecular level, activation of
the transcription factor NF-kB leads to
the production of multiple mediators of
inflammation. Stimuli that can activate
NF-kB in obesity can be separated into
extracellular ligands, such as the proin-
flammatory cytokines TNF-a, IL-1b,
and IL-6 or fatty acids binding to Toll-
like receptors, and intracellular stimuli,
such as endoplasmic reticulum or oxida-
tive stress and ceramides (2). These pro-
cesses are associated with both T2D and
increased atherosclerotic risk and thus
could provide novel therapeutic targets
to treat or prevent either or both pro-
cesses. However, the overlap in inflam-
matory mechanisms driving diabetes
and cardiovascular disease remains in-
completely understood. The effect of
NF-kB on the vasculature may occur
through regulation of adipokines and cy-
tokines that lead to vascular injury or by
reducing insulin sensitivity within the
endothelium, which normally signals
the phosphatidylinositol-3 kinase and
Akt/protein kinase B pathway, leading
to activation of endothelial nitric oxide
synthase.
Multiple studies demonstrate that
high-dose salicylates inhibit activity of
NF-kB (34–36), which regulates tran-
scription of numerous inflammatory
mediators. Compared with aspirin,
salsalate, a nonacetylated dimer of salicy-
late, is an equipotent inhibitor of NF-kB
but a much weaker inhibitor of the cyclo-
oxygenase enzymes; therefore it is not as-
sociated with an increased risk of
bleeding and is clinically safer. While sa-
licylates inhibit NF-kB signaling, they
may have additional cellular and molecu-
lar mechanisms of action. These include
inhibition of mitochondrial dehydroge-
nases; transcription factors other than
NF-kB (e.g., cAMP-responsive element–
binding protein, NF of activated T cells,
heat shock transcription factor-1); and cel-
lular kinases (inhibitor of kB kinase-b, S6-
kinase, p38 mitogen-activate protein
kinase, ribosomal protein S6 kinase 2, Jun
NH2-terminal kinase) (37–41). Salicylate
alsomay inhibit 11-b-hydroxysteroid de-
hydrogenase type 1 in adipose tissue (42)
and activate AMP-activated protein ki-
nase (43). It is difficult to distinguish
the relative in vivo contributions of these
potential mechanisms.
Finally, it is difficult to determine
whether salsalate should be further de-
veloped as a diabetes therapy given the
mixed effects on metabolic markers of
vascular healthdincluding glycemic im-
provement, increased adiponectin, and
lowered WBC, triglyceride, and uric acid
levelsdin the setting of increased LDL
cholesterol and urinary albumin. Addi-
tional studies are underway to target in-
flammation using salsalate in patients
with diverse diseases, including schizo-
phrenia, anemia, myelodysplastic syn-
dromes, spinal cord injury, polycystic
ovarian syndrome, and chronic obstruc-
tive pulmonary disease. Understanding
the cardiovascular impact of medications
that would be intended for chronic use is
of high clinical importance, but the neu-
tral effect on endothelium-dependent di-
lation is especially important given the
many potential diseases that might im-
prove with targeted inflammatory
response.
In conclusion, in this study we tar-
geted inflammation in patients with T2D
using a clinically tolerable dose of salsa-
late over 6 months to evaluate the effect
on atherosclerotic risk as assessed by a
measure of endothelial function. We did
not find a change, either improvement or
worsening, in FMD of the brachial artery, a
surrogate measure of nitric oxide bioactiv-
ity, despite lowering HbA1c and markers of
inflammation. These observations suggest
that either inflammation does not cause en-
dothelial dysfunction in T2D, that salsalate
does not adequately inhibit inflammation
of the vasculature, or that confounding ef-
fects of salsalate mitigate favorable effects
on endothelial function. Yet while there
was nomeasurable net effect on endothelial
function, anti-inflammatory interventions
potentially have other favorable effects on
cardiovascular outcomes by interfering
with the atherosclerotic process elsewhere.
At this time, however, the net effects of sal-
salate on vascular health, as assessed by
FMD, seem to be neutral, and further study
is warranted before widespread use.
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